Invivyd Inc (IVVD)

Jul 23, 2025

Invivyd Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome - The Manila Times

Jul 23, 2025

Jul 23, 2025

Yale immunobiologist Iwasaki joins Invivyd’s Long COVID research group - Investing.com

Jul 23, 2025

Jul 23, 2025

Yale immunobiologist Iwasaki joins Invivyd’s Long COVID research group By Investing.com - Investing.com South Africa

Jul 23, 2025

Jul 23, 2025

Invivyd, Inc.'s (NASDAQ:IVVD) Shift From Loss To Profit - simplywall.st

Jul 23, 2025

Jul 23, 2025

What analysts say about Invivyd Inc. stockTremendous financial leverage - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Is Invivyd Inc. a good long term investmentMassive stock growth - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

What drives Invivyd Inc. stock priceAccelerated investment success - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

How Invivyd Inc. stock performs during market volatilityFree Stock Market Swing Trading Strategies - Newser

Jul 22, 2025

Jul 17, 2025

Goldman Sachs Shines in Q2 2025 Earnings Call - The Globe and Mail

Jul 17, 2025

Jul 15, 2025

Why Invivyd Inc. stock attracts strong analyst attentionFree Consultation - Newser

Jul 15, 2025

Jul 15, 2025

What makes Invivyd Inc. stock price move sharplyFree VIP Investment Strategies - Newser

Jul 15, 2025

Jul 14, 2025

Why Shares of Nebius Group Are Rocketing Higher Today - The Globe and Mail

Jul 14, 2025

Jul 02, 2025

Invivyd Launches SPEAR Study for Long COVID Therapy - TipRanks

Jul 02, 2025

Jul 02, 2025

Invivyd forms research group to study monoclonal antibodies for Long COVID - Investing.com

Jul 02, 2025

Jul 02, 2025

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome - TradingView

Jul 02, 2025

Jun 27, 2025

Invivyd (IVVD) Receives Continued 'Buy' Rating from D. Boral Cap - GuruFocus

Jun 27, 2025

Jun 27, 2025

H.C. Wainwright maintains buy rating on Invivyd stock after positive data - Investing.com

Jun 27, 2025

Jun 26, 2025

Invivyd’s COVID-19 antibody shows promising safety profile in trial - Investing.com

Jun 26, 2025

Jun 26, 2025

Invivyd Announces Positive Phase 1/2 Trial Results - TipRanks

Jun 26, 2025

Jun 16, 2025

Trading Day Triumph: Invivyd Inc (IVVD) Ends at 0.79, a -6.47 Surge/Plunge - DWinneX

Jun 16, 2025

Jun 02, 2025

COVID’s remaining biotech contenders navigate a dwindling market - Pharma Voice

Jun 02, 2025

May 29, 2025

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall - Insider Monkey

May 29, 2025

May 29, 2025

Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating - Investing.com Nigeria

May 29, 2025

May 29, 2025

Invivyd (NASDAQ:IVVD) Price Target Lowered to $5.00 at HC Wainwright - Defense World

May 29, 2025

May 28, 2025

Invivyd (IVVD) Analyst Rating Update: Price Target Lowered | IVV - GuruFocus

May 28, 2025

May 28, 2025

Invivyd (IVVD) Price Target Reduced by H.C. Wainwright Amid Revenue Concerns | IVVD Stock News - GuruFocus

May 28, 2025

May 27, 2025

Invivyd (IVVD) Publishes Strong Phase 3 Trial Results for COVID-19 Antibody | IVVD Stock News - GuruFocus

May 27, 2025

May 27, 2025

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive S - The Manila Times

May 27, 2025